Each Mylan share will be converted into a share of the new company. Pfizer shareholders will own 57% of the new entity, with Mylan shareholders owning the rest.
It will create a new pharmaceutical firm with forecast pro-forma 2020 revenues of around $20bn, with pro-forma Ebitda for the same
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: email@example.com or find out more online here.